.jetcityimage/iStock Content via Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its best biopharma selection for 2025 as well as ranked an additional nine titles in the area as over weight. The investment bank mentioned in a note that it continues to strongly believe “diabesity is actually readied to come to be.